VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s): VPTDF

Healthcare Medical Devices

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.

TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > Engines getting lubed up big volume $$ wall 0.52

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Oct 21, 2021 9:23am

124 Views

Post# 34031816

RE:RE:RE:RE:RE:Engines getting lubed up big volume $$ wall 0.52

Snuff, I'm assuming the word "delayed" in #5 should be "deployed" or ??

snuff133 wrote:
Another install but the most important part of this email is number 6 , have a read and let me know what you Think. That's one of many game changers coming down the pipe

Dear Friend;

Attached is today’s news release.

Here are some background points:

1.      East Midlands has had a version VMS+1.0 for 5 years and so is one of our users with a long experience effectively using the device.
2.      Dr. Skinner has built a pan-European and Middle-East referral practice due to the VMS+ and has patients coming to his clinic specifically to be scanned by the VMS+
3.      He has been reviewing his data and expects to publish a landmark paper concerning “trend-line” analysis in CHD patients and the optimal point-of-intervention for valve replacement.
4.      Kings College in London has the second unit, which is being used for acute and chronic COVID-19 patients.
5.      With this installation, we now have 20 VMS+3.0 delayed at major cardiac centres in USA,Canada, Europe and China.
6.      We are working with a distributor in the UK to finalize an agreement and they will be using Dr. Skinner as a reference center for potential customers.
7.      East Midlands (Glenfield Hospital) has been named one for the forty COVID-19 special clinics being setup in the UK to treat long-haul COVID-19 patients.
8.      A recent meta-analysis of long-haul COVID clinical studies found 62% of patients had some lingering chest issues (heart and lung) that lasted at least 6 months.

Thank you for your continued support and interest.

Regards,